Compare Dishman Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs CIPLA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA CIPLA DISHMAN PHARMA/
CIPLA
 
P/E (TTM) x 25.1 35.6 70.5% View Chart
P/BV x 3.3 4.1 81.0% View Chart
Dividend Yield % 0.7 0.5 134.2%  

Financials

 DISHMAN PHARMA   CIPLA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
CIPLA
Mar-20
DISHMAN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs374586 63.9%   
Low Rs129357 36.1%   
Sales per share (Unadj.) Rs197.8207.0 95.5%  
Earnings per share (Unadj.) Rs21.218.6 114.0%  
Cash flow per share (Unadj.) Rs34.733.2 104.7%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.80.8 93.6%  
Book value per share (Unadj.) Rs179.9195.5 92.0%  
Shares outstanding (eoy) m80.69806.35 10.0%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x1.32.3 55.9%   
Avg P/E ratio x11.925.3 46.8%  
P/CF ratio (eoy) x7.214.2 51.0%  
Price / Book Value ratio x1.42.4 58.0%  
Dividend payout %9.421.5 43.8%   
Avg Mkt Cap Rs m20,306379,912 5.3%   
No. of employees `0000.825.8 3.2%   
Total wages/salary Rs m5,35530,270 17.7%   
Avg. sales/employee Rs Th19,252.76,459.6 298.0%   
Avg. wages/employee Rs Th6,459.51,171.2 551.5%   
Avg. net profit/employee Rs Th2,064.1580.2 355.8%   
INCOME DATA
Net Sales Rs m15,961166,949 9.6%  
Other income Rs m2653,442 7.7%   
Total revenues Rs m16,226170,391 9.5%   
Gross profit Rs m4,10332,060 12.8%  
Depreciation Rs m1,09111,747 9.3%   
Interest Rs m9441,974 47.9%   
Profit before tax Rs m2,33421,782 10.7%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6246,312 9.9%   
Profit after tax Rs m1,71114,995 11.4%  
Gross profit margin %25.719.2 133.9%  
Effective tax rate %26.729.0 92.2%   
Net profit margin %10.79.0 119.4%  
BALANCE SHEET DATA
Current assets Rs m11,018117,038 9.4%   
Current liabilities Rs m9,51743,931 21.7%   
Net working cap to sales %9.443.8 21.5%  
Current ratio x1.22.7 43.5%  
Inventory Days Days11096 115.4%  
Debtors Days Days3585 40.9%  
Net fixed assets Rs m16,304107,424 15.2%   
Share capital Rs m1611,613 10.0%   
"Free" reserves Rs m12,907156,018 8.3%   
Net worth Rs m14,516157,630 9.2%   
Long term debt Rs m4,18923,693 17.7%   
Total assets Rs m29,805236,626 12.6%  
Interest coverage x3.512.0 28.8%   
Debt to equity ratio x0.30.2 192.0%  
Sales to assets ratio x0.50.7 75.9%   
Return on assets %8.97.2 124.2%  
Return on equity %11.89.5 123.9%  
Return on capital %17.512.8 136.5%  
Exports to sales %24.833.0 75.0%   
Imports to sales %3.70-   
Exports (fob) Rs m3,95655,175 7.2%   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95256,036 8.8%   
Fx outflow Rs m6976,764 10.3%   
Net fx Rs m4,25549,272 8.6%   
CASH FLOW
From Operations Rs m2,78630,685 9.1%  
From Investments Rs m-1,5291,040 -147.0%  
From Financial Activity Rs m-941-29,488 3.2%  
Net Cashflow Rs m3162,340 13.5%  

Share Holding

Indian Promoters % 61.4 16.0 383.8%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 3.7 12.2 30.3%  
FIIs % 12.7 23.7 53.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 22.1 26.2 84.4%  
Shareholders   46,261 161,166 28.7%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  SHASUN PHARMA  NOVARTIS  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS